These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 37355592)

  • 1. Different hydration methods for the prevention of contrast-induced nephropathy in patients with elective percutaneous coronary intervention: a retrospective study.
    Chen F; Lu J; Yang X; Liu D; Wang Q; Geng X; Xiao B; Zhang J; Liu F; Gu G; Cui W
    BMC Cardiovasc Disord; 2023 Jun; 23(1):323. PubMed ID: 37355592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of alprostadil in preventing contrast-induced nephropathy in patients undergoing percutaneous coronary intervention: A multicenter prospective randomized controlled trial.
    Liang M; Yang S; Fu N; Lu C; Tian F; Xing X; Lin W; Liu J
    Catheter Cardiovasc Interv; 2018 Mar; 91(4):742-750. PubMed ID: 29024304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy of probucol combined with hydration in preventing contrast-induced nephropathy in patients with coronary heart disease undergoing percutaneous coronary intervention: a multicenter, prospective, randomized controlled study.
    Fu N; Yang S; Zhang J; Zhang P; Liang M; Cong H; Lin W; Tian F; Lu C
    Int Urol Nephrol; 2018 Jan; 50(1):105-112. PubMed ID: 29071556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Febuxostat combined with hydration for the prevention of contrast-induced nephropathy in hyperuricemia patients undergoing percutaneous coronary intervention: A CONSORT-compliant randomized controlled trial.
    Ma G; Li M; Teng W; He Z; Zhai X; Xia Z
    Medicine (Baltimore); 2022 Jan; 101(4):e28683. PubMed ID: 35089218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Vigileo/FloTrac System-Guided Aggressive Hydration in Acute Myocardial Infarction Patients to Prevent Contrast-Induced Nephropathy After Urgent Percutaneous Coronary Intervention.
    Ling W; Jiang Z; Liu K; Zhang H; Qian Y; Tian J; Zhang Z; Chen Y; Qian G
    Am J Cardiol; 2023 May; 195():77-82. PubMed ID: 37018968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contrast-Induced Nephropathy After Percutaneous Coronary Intervention for Chronic Total Occlusion Versus Non-Occlusive Coronary Artery Disease.
    Demir OM; Lombardo F; Poletti E; Laricchia A; Beneduce A; Maccagni D; Slavich M; Giannini F; Carlino M; Margonato A; Cappelletti A; Colombo A; Azzalini L
    Am J Cardiol; 2018 Dec; 122(11):1837-1842. PubMed ID: 30292337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glycosylated hemoglobin levels and the risk for contrast-induced nephropathy in diabetic patients undergoing coronary arteriography/percutaneous coronary intervention.
    Zhang H; Fu H; Fu X; Zhang J; Zhang P; Yang S; Zeng Z; Fu N; Guo Z
    BMC Nephrol; 2021 Jun; 22(1):206. PubMed ID: 34078303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A simple risk score model for predicting contrast-induced nephropathy after coronary angiography in patients with diabetes.
    Zeng JF; Chen SQ; Ye JF; Chen Y; Lei L; Liu XQ; Liu Y; Wang Y; Lin JJ; Chen JY
    Clin Exp Nephrol; 2019 Jul; 23(7):969-981. PubMed ID: 31049747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of minimum contrast media volumes during elective percutaneous coronary intervention for prevention of contrast-induced nephropathy in patients with stable coronary artery disease.
    Ebisawa S; Kurita T; Tanaka N; Nasu K; Kimura M; Ito T; Kinoshita Y; Tsuchikane E; Terashima M; Suzuki T
    Cardiovasc Interv Ther; 2016 Jan; 31(1):13-20. PubMed ID: 26001976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel risk assessment model of contrast-induced nephropathy after percutaneous coronary intervention in patients with diabetes.
    Yao ZF; Shen H; Tang MN; Yan Y; Ge JB
    Basic Clin Pharmacol Toxicol; 2021 Feb; 128(2):305-314. PubMed ID: 32991776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant Brain Natriuretic Peptide for the Prevention of Contrast-Induced Nephropathy in Patients with Chronic Kidney Disease Undergoing Nonemergent Percutaneous Coronary Intervention or Coronary Angiography: A Randomized Controlled Trial.
    Liu J; Xie Y; He F; Gao Z; Hao Y; Zu X; Chang L; Li Y
    Biomed Res Int; 2016; 2016():5985327. PubMed ID: 26949703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Risk factors of contrast-induced nephropathy after percutaneous coronary intervention in patients with coronary heart disease and the countermeasures].
    Zheng H; Tu Y; Ma LQ
    Nan Fang Yi Ke Da Xue Xue Bao; 2011 Jun; 31(7):1273-6. PubMed ID: 21764713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of intravenous hydration on risk of contrast induced nephropathy and in-hospital mortality in STEMI patients undergoing primary percutaneous coronary intervention: a systematic review and meta-analysis of randomized controlled trials.
    Liu Y; Hong D; Wang AY; Guo R; Smyth B; Liu J; Sun G; Chen S; Tan N; Jardine M; Brieger D; Shaman A; Islam S; Chen J; Gallagher M
    BMC Cardiovasc Disord; 2019 Apr; 19(1):87. PubMed ID: 30961544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated high-sensitivity C-reactive protein combined with procalcitonin predicts high risk of contrast-induced nephropathy after percutaneous coronary intervention.
    Gu G; Yuan X; Zhou Y; Liu D; Cui W
    BMC Cardiovasc Disord; 2019 Jun; 19(1):152. PubMed ID: 31234798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trimetazidine can prevent the occurrence of contrast-induced nephropathy after percutaneous coronary intervention in elderly patients with renal insufficiency.
    Fu H; Zhang J; Zhang H; Zhang P; Fu X; Zeng Z; Zhang X; Li W; Yang S; Liu X; Fu N
    Perfusion; 2021 Sep; 36(6):603-609. PubMed ID: 32909511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased urinary adiponectin level is associated with contrast-induced nephropathy in patients undergoing elective percutaneous coronary intervention.
    Zhang JY; Wang Q; Wang RT; Li F; Cheng HX; Lian K; Liu Y; Tao L
    BMC Cardiovasc Disord; 2019 Jul; 19(1):160. PubMed ID: 31269899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CHA2DS2-VASC score as a preprocedural predictor of contrast-induced nephropathy among patients with chronic total occlusion undergoing percutaneous coronary intervention: a single-center experience.
    Wang Y; Zhao HW; Zhang XJ; Chen BJ; Yu GN; Hou AJ; Luan B
    BMC Cardiovasc Disord; 2019 Mar; 19(1):74. PubMed ID: 30922230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effect of probucol on preventing contrast-induced nephropathy in patients undergoing percutaneous coronary intervention].
    Suo XQ; Yang SC; Ma ZH; Sun TT; Zhang WY; Cong HL; Lin WH; Lu CZ; Tian FS; Fu NK
    Zhonghua Yi Xue Za Zhi; 2017 Nov; 97(41):3234-3238. PubMed ID: 29141361
    [No Abstract]   [Full Text] [Related]  

  • 19. The association of PRECISE-DAPT score with development of contrast-induced nephropathy in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Çınar T; Tanık VO; Aruğaslan E; Karabağ Y; Çağdaş M; Rencüzoğulları İ; Keskin M
    Cardiovasc Interv Ther; 2019 Jul; 34(3):207-215. PubMed ID: 30191494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin Resistance Increases the Risk of Contrast-Induced Nephropathy in Patients Undergoing Elective Coronary Intervention.
    Li Y; Liu Y; Shi D; Yang L; Liang J; Zhou Y
    Angiology; 2016 Feb; 67(2):139-45. PubMed ID: 25843952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.